IL111196A0 - Peptides and pharmaceutical compositions comprising them - Google Patents

Peptides and pharmaceutical compositions comprising them

Info

Publication number
IL111196A0
IL111196A0 IL11119694A IL11119694A IL111196A0 IL 111196 A0 IL111196 A0 IL 111196A0 IL 11119694 A IL11119694 A IL 11119694A IL 11119694 A IL11119694 A IL 11119694A IL 111196 A0 IL111196 A0 IL 111196A0
Authority
IL
Israel
Prior art keywords
cells
peptides
pharmaceutical compositions
idiotypic
activity
Prior art date
Application number
IL11119694A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11119694A priority Critical patent/IL111196A0/xx
Publication of IL111196A0 publication Critical patent/IL111196A0/xx
Priority to IL11551895A priority patent/IL115518A/xx
Priority to JP8512640A priority patent/JPH10507345A/ja
Priority to EP95937323A priority patent/EP0783524B1/en
Priority to DE69534024T priority patent/DE69534024T2/de
Priority to PL95319831A priority patent/PL319831A1/xx
Priority to CZ971031A priority patent/CZ103197A3/cs
Priority to KR1019970702283A priority patent/KR100381711B1/ko
Priority to AT95937323T priority patent/ATE289611T1/de
Priority to US08/817,177 priority patent/US6096314A/en
Priority to FI971427A priority patent/FI971427A7/fi
Priority to HU9800152A priority patent/HUT77484A/hu
Priority to CA002201935A priority patent/CA2201935A1/en
Priority to AU39462/95A priority patent/AU708301B2/en
Priority to PCT/US1995/012686 priority patent/WO1996011214A1/en
Priority to SK441-97A priority patent/SK44197A3/sk
Priority to NO971517A priority patent/NO971517L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL11119694A 1994-10-07 1994-10-07 Peptides and pharmaceutical compositions comprising them IL111196A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL11119694A IL111196A0 (en) 1994-10-07 1994-10-07 Peptides and pharmaceutical compositions comprising them
IL11551895A IL115518A (en) 1994-10-07 1995-10-05 Peptides and pharmaceutical compositions comprising them
SK441-97A SK44197A3 (en) 1994-10-07 1995-10-10 Peptides modulating the activity of anti-idiotypic t-cells and pharmaceutical compositions containing them, usable in diagnostics and therapy of diabetes mellitus of i.type
CZ971031A CZ103197A3 (en) 1994-10-07 1995-10-10 Peptides modulating activity of anti-idiotype t cells and pharmaceutical preparations containing thereof and being usable in diagnostics and diabetes mellitus treatment
US08/817,177 US6096314A (en) 1994-10-07 1995-10-10 Peptides and pharmaceutical compositions comprising them
DE69534024T DE69534024T2 (de) 1994-10-07 1995-10-10 Peptide und pharmazeutische zusammensetzungen, die diese enthalten
PL95319831A PL319831A1 (en) 1994-10-07 1995-10-10 Peptides and pharmaceutic compositions containing such peptides
JP8512640A JPH10507345A (ja) 1994-10-07 1995-10-10 ペプチド及びこれを含む薬剤組成物
KR1019970702283A KR100381711B1 (ko) 1994-10-07 1995-10-10 펩티드들과그들을포함하는약학적조성물들
AT95937323T ATE289611T1 (de) 1994-10-07 1995-10-10 Peptide und pharmazeutische zusammensetzungen, die diese enthalten
EP95937323A EP0783524B1 (en) 1994-10-07 1995-10-10 Peptides and pharmaceutical compositions comprising them
FI971427A FI971427A7 (fi) 1994-10-07 1995-10-10 Peptidit ja niitä sisältävät farmaseuttiset koostumukset
HU9800152A HUT77484A (hu) 1994-10-07 1995-10-10 Peptidek és ezeket tartalmazó gyógyszerkészítmények
CA002201935A CA2201935A1 (en) 1994-10-07 1995-10-10 Peptides and pharmaceutical compositions comprising them
AU39462/95A AU708301B2 (en) 1994-10-07 1995-10-10 Peptides and pharmaceutical compositions comprising them
PCT/US1995/012686 WO1996011214A1 (en) 1994-10-07 1995-10-10 Peptides and pharmaceutical compositions comprising them
NO971517A NO971517L (no) 1994-10-07 1997-04-03 Peptider og farmasöytiske sammensetninger omfattende dem

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11119694A IL111196A0 (en) 1994-10-07 1994-10-07 Peptides and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
IL111196A0 true IL111196A0 (en) 1994-12-29

Family

ID=11066614

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11119694A IL111196A0 (en) 1994-10-07 1994-10-07 Peptides and pharmaceutical compositions comprising them

Country Status (15)

Country Link
EP (1) EP0783524B1 (cs)
JP (1) JPH10507345A (cs)
KR (1) KR100381711B1 (cs)
AT (1) ATE289611T1 (cs)
AU (1) AU708301B2 (cs)
CA (1) CA2201935A1 (cs)
CZ (1) CZ103197A3 (cs)
DE (1) DE69534024T2 (cs)
FI (1) FI971427A7 (cs)
HU (1) HUT77484A (cs)
IL (1) IL111196A0 (cs)
NO (1) NO971517L (cs)
PL (1) PL319831A1 (cs)
SK (1) SK44197A3 (cs)
WO (1) WO1996011214A1 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP3122768A2 (en) * 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
CN120699093B (zh) * 2025-06-26 2026-04-14 华中农业大学 一种蛋黄源降血糖肽及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof

Also Published As

Publication number Publication date
DE69534024D1 (de) 2005-03-31
EP0783524B1 (en) 2005-02-23
CA2201935A1 (en) 1996-04-18
CZ103197A3 (en) 1997-09-17
KR970706306A (ko) 1997-11-03
SK44197A3 (en) 1997-11-05
FI971427A0 (fi) 1997-04-04
EP0783524A4 (en) 2000-05-17
NO971517L (no) 1997-05-22
FI971427L (fi) 1997-05-26
AU3946295A (en) 1996-05-02
NO971517D0 (no) 1997-04-03
PL319831A1 (en) 1997-09-01
AU708301B2 (en) 1999-07-29
JPH10507345A (ja) 1998-07-21
DE69534024T2 (de) 2006-01-12
ATE289611T1 (de) 2005-03-15
EP0783524A1 (en) 1997-07-16
FI971427A7 (fi) 1997-05-26
HUT77484A (hu) 1998-05-28
KR100381711B1 (ko) 2003-07-16
WO1996011214A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
CA2219988A1 (en) Cd16-ii variants
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
ATE183514T1 (de) Peptide des menschlichen proteins p53 zum gebrauch in menschlichen-zytotoxischen-t-zell- antwort-induzierenden kompositionen sowie menschliche p53-protein-spezifische t-lymphocyten
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
IL111196A0 (en) Peptides and pharmaceutical compositions comprising them
PL321091A1 (en) Analogues of peptide p@&& and pharmaceutic sets of components containing them, used in treatment or diagnosis of diabetes
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
AU7411398A (en) Improved methods for the diagnosis and treatment of insulin depdende nt diabete s mellitus
CA2023246A1 (en) Mutants of human interleukin-3
ATE510018T1 (de) Synthetische menschliche gene und polypeptide und deren verwendung in der behandlung von autoimmunkrankheiten
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
EP0917535A4 (en) NEURO-ACTIVE PEPTIDE
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
WO1998042737A3 (en) Peptides for the treatment of systemic lupus erythematosus
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
ATE183652T1 (de) Synthetische peptide für die behandlung von myasthenia gravis
ATE103979T1 (de) Menschliches lymphotoxin.
NO964688D0 (no) Ny peptid-aktivsubstans og fremstilling av denne
WO1999050671A3 (en) Toso as a target for drug screening